See more : China Fortune Financial Group Limited (0290.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Nutriband Inc. (NTRBW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nutriband Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nikon Corporation (NINOY) Income Statement Analysis – Financial Results
- Personal Assets Trust plc (PNL.L) Income Statement Analysis – Financial Results
- Ashtead Group plc (ASHTF) Income Statement Analysis – Financial Results
- Orbia Advance Corporation, S.A.B. de C.V. (MXCHF) Income Statement Analysis – Financial Results
- Tungtex (Holdings) Company Limited (TUGHF) Income Statement Analysis – Financial Results
Nutriband Inc. (NTRBW)
About Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.09M | 2.08M | 1.42M | 943.70K | 370.65K | 245.29K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.22M | 1.33M | 917.84K | 582.38K | 549.11K | 288.30K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 862.11K | 750.41K | 504.31K | 361.32K | -178.46K | -43.02K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 41.34% | 36.08% | 35.46% | 38.29% | -48.15% | -17.54% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.96M | 982.23K | 411.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 4.02M | 2.91M | 0.00 | 0.00 | 0.00 | 143.49K | 4.80K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 45.00K | 0.00 | 0.00 | 0.00 | 7.77K | -4.40K |
| SG&A | 3.77M | 3.92M | 4.02M | 2.96M | 1.79M | 3.29M | 171.95K | 151.26K | 400.00 |
| Other Expenses | 0.00 | 327.33K | 2.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.73M | 4.90M | 4.43M | 2.96M | 1.79M | 3.29M | 171.95K | 151.26K | 400.00 |
| Cost & Expenses | 6.96M | 6.23M | 5.35M | 3.54M | 2.34M | 3.58M | 171.95K | 151.26K | 400.00 |
| Interest Income | 16.85K | 8.29K | 118.42K | 280.69K | 73.41K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 75.82K | 8.29K | 118.42K | 280.69K | 73.41K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 287.72K | 368.96K | 318.26K | 169.72K | 91.84K | 37.01K | 147.26K | 151.26K | 4.80K |
| EBITDA | -5.12M | -4.11M | -5.74M | -2.48M | -2.56M | -3.29M | -2.67M | 0.00 | -400.00 |
| EBITDA Ratio | -245.61% | -181.71% | -253.96% | -264.42% | -506.69% | -1,343.02% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.87M | -4.15M | -3.93M | -2.60M | -1.97M | -3.33M | -171.95K | -151.26K | -400.00 |
| Operating Income Ratio | -233.63% | -199.45% | -276.33% | -275.08% | -531.35% | -1,358.11% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -613.39K | -335.62K | -2.25M | -336.88K | -752.19K | 0.00 | -2.50M | 0.00 | 0.00 |
| Income Before Tax | -5.49M | -4.48M | -6.18M | -2.93M | -2.72M | -3.33M | -2.67M | -151.26K | -400.00 |
| Income Before Tax Ratio | -263.04% | -215.59% | -434.28% | -310.78% | -734.29% | -1,358.11% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 327.33K | 2.25M | 280.69K | 73.41K | -124.13K | 2.35M | -151.26K | -4.80K |
| Net Income | -5.49M | -4.81M | -8.42M | -3.21M | -2.80M | -3.33M | -2.67M | -151.26K | -400.00 |
| Net Income Ratio | -263.04% | -231.33% | -592.23% | -340.52% | -754.10% | -1,358.11% | 0.00% | 0.00% | 0.00% |
| EPS | -0.69 | -0.57 | -1.06 | -0.48 | -0.44 | -0.53 | -0.48 | -0.03 | 0.00 |
| EPS Diluted | -0.69 | -0.57 | -1.06 | -0.48 | -0.44 | -0.53 | -0.48 | -0.03 | 0.00 |
| Weighted Avg Shares Out | 7.95M | 8.46M | 7.93M | 6.73M | 6.33M | 6.24M | 5.60M | 6.06M | 6.06M |
| Weighted Avg Shares Out (Dil) | 7.95M | 8.46M | 7.93M | 6.73M | 6.33M | 6.24M | 5.60M | 6.06M | 6.06M |
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
ORLANDO, FL / ACCESSWIRE / July 15, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on July 9, 2024,...
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
ORLANDO, FL / ACCESSWIRE / June 20, 2024 / Nutriband Inc.("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) provides an update on its Aversa Fentanyl product development program to shareholders as it aims to complete scale-up of the commercial manufacturing process and move towards the single...
Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year
ORLANDO, FL / ACCESSWIRE / June 3, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today reported Q1 revenues of $408,532 emphasizing its focus on expanding the company's Kinesiology Tape manufacturing services through its Pocono Pharma subsidiary. The Company has been focused on...
Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors
The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placement ORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka...
Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group
ORLANDO, FL / ACCESSWIRE / April 23, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that following its engagement by Fit For Life Group (FFL), a major brand license holder, on April 19, 2024, the companies fully executed an exclusive Supplier...
Nutriband Inc. Announces $8.4M Private Placement
Nutriband is targeting a 505(b)(2) NDA to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025 ORLANDO, FL / ACCESSWIRE / April 19, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical...
Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting
Data highlights the incidence of abuse and accidental pediatric exposure of transdermal patches containing opioid and stimulant drugs Nutriband's AVERSA™ technology addresses the unmet need for safer abuse-deterrent transdermal patches ORLANDO, FL / ACCESSWIRE / March 25, 2024 / Nutriband...
Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting
ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that data on the incidence of transdermal patch abuse and accidental pediatric exposure will be...
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st. ORLANDO, FL / ACCESSWIRE / January 29, 2024 / Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Dealflow Events MicroCap Conference...
Nutriband CEO Publishes Letter to Shareholders
ORLANDO, FL / ACCESSWIRE / January 26, 2024 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and targets through 2023 and the potential outlook for 2024. The...
Source: https://incomestatements.info
Category: Stock Reports